Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL720797 | 0.74 | ALDH1A1 (0.44) | IMPDH2 | |
| SCHEMBL10709835 | 0.69 | IMPDH2 (0.46) | IMPDH2 | |
| SCHEMBL6623767 | 0.65 | CCR4 (0.52) | — | |
| SCHEMBL16657394 | 0.65 | ALDH1A1 (0.36) | MAPK10 | |
| SCHEMBL27456494 | 0.64 | MAPK10 (0.51) | MAPK10 | |
| SCHEMBL9235086 | 0.64 | IMPDH2 (0.46) | IMPDH2 | |
| SCHEMBL1570705 | 0.63 | GABRA1 (0.47) | IMPDH2 | |
| SCHEMBL544111 | 0.62 | MEN1 (0.50) | — | |
| SCHEMBL29949337 | 0.62 | EGFR (0.32) | — | |
| SCHEMBL26965586 | 0.62 | EGFR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146585-A1 | Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy | AB SCIENCE | 2008-06-19 | — | — | US | disclosed |
| US-20080004279-A1 | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | AB SCIENCE (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20070249628-A1 | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons | MOUSSY ALAIN | 2007-10-25 | — | — | US | disclosed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146585-A1 | Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy | KIT, CPA3, CMA1 | IMPDH2 3520/4885MAPK10 1085/4885 |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | KIT, CPA3, CMA1 | IMPDH2 3798/4885MAPK10 1012/4885 |
| US-20080004279-A1 | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | KIT, JAK3, MAP3K3 | IMPDH2 2423/4885MAPK10 380/4885 |
| US-20070249628-A1 | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons | KIT, CPA3, CMA1 | IMPDH2 3523/4885MAPK10 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.